In last trading session, Inozyme Pharma Inc. (NASDAQ:INZY) saw 0.45 million shares changing hands with its beta currently measuring 0. Company’s recent per share price level of $1.55 trading at $0.07 or 4.73% at ring of the bell on the day assigns it a market valuation of $62.00M. That closing price of INZY’s stock is at a discount of -498.06% from its 52-week high price of $9.27 and is indicating a premium of 6.45% from its 52-week low price of $1.45. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 61970.0 shares which gives us an average trading volume of 66.77K if we extend that period to 3-months.
Inozyme Pharma Inc. (NASDAQ:INZY) trade information
Upright in the green during last session for gaining 4.73%, in the last five days INZY remained trading in the red while hitting it’s week-highest on Thursday, 11/17/22 when the stock touched $1.55 price level, adding 10.4% to its value on the day. Inozyme Pharma Inc.’s shares saw a change of -77.27% in year-to-date performance and have moved -1.27% in past 5-day. Inozyme Pharma Inc. (NASDAQ:INZY) showed a performance of -29.86% in past 30-days. Number of shares sold short was 0.17 million shares which calculate 3.13 days to cover the short interests.
Inozyme Pharma Inc. (INZY) estimates and forecasts
Statistics highlight that Inozyme Pharma Inc. is scoring comparatively higher than the scores of other players of the relevant industry. The company lost -61.25% of value to its shares in past 6 months, showing an annual growth rate of 23.75% while that of industry is 4.60. Apart from that, the company came raising its revenue forecast for fiscal year 2022. The company is estimating its revenue growth to increase by 28.30% in the current quarter and calculating 44.30% increase in the next quarter.
In 2022, company’s earnings growth rate is likely to be around 0.40% while estimates for its earnings growth in next 5 years are of 16.40%.
Inozyme Pharma Inc. is more likely to be releasing its next quarterly report between November 07 and November 11 and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
Inozyme Pharma Inc. (NASDAQ:INZY)’s Major holders
Insiders are in possession of 1.43% of company’s total shares while institution are holding 89.05 percent of that, with stock having share float percentage of 90.34%. Investors also watch the number of corporate investors in a company very closely, which is 89.05% institutions for Inozyme Pharma Inc. that are currently holding shares of the company. Sofinnova Investments, Inc. is the top institutional holder at INZY for having 3.66 million shares of worth $17.44 million. And as of Jun 29, 2022, it was holding 9.11% of the company’s outstanding shares.
The second largest institutional holder is Deep Track Capital, LP, which was holding about 3.25 million shares on Jun 29, 2022. The number of shares represents firm’s hold over 8.10% of outstanding shares, having a total worth of $15.5 million.
On the other hand, Vanguard Total Stock Market Index Fund and Fidelity Select Portfolios – Biotechnology are the top two Mutual Funds which own company’s shares. As of Jun 29, 2022, the former fund manager was holding 0.84 million shares of worth $4.02 million or 2.10% of the total outstanding shares. The later fund manager was in possession of 0.61 million shares on Jun 29, 2022, making its stake of worth around $2.91 million in the company or a holder of 1.52% of company’s stock.